B.C. Oncology SA
B.C. Oncology reported total assets of €9.50m at the end of the 2025 financial year (annual accounts filed with the NBB on 22 May 2026).
By total assets for 2025, B.C. Oncology ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of B.C. Oncology shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity 0 % Total assets 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
B.C. Oncology's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 22 May 2026
- Year ended 31 Dec 2024filed on 03 Jul 2025
- Year ended 31 Dec 2023filed on 06 Jun 2024
- Year ended 31 Dec 2022filed on 09 Jun 2023
- Year ended 31 Dec 2021filed on 18 Jul 2022
B.C. Oncology's financial analysis
- Solvency99.8%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of B.C. Oncology
B.C. Oncology's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0629.859.206
- VAT number
- BE0629859206
- Peppol
- Not found on Peppol as of 11 Nov 2026 · Check
- Legal form
- SA
- Incorporated
- 07 May 2015
- Registered office
- 1930 Zaventem
- Latest accounts
- 2025 · filed on 22 May 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
B.C. Oncology (SA) has been based in Zaventem since 2015, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 5,396 € and equity of €9.48m; its revenue is not published. Its solvency stands at 99.8%, above the median of its sector (61.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to B.C. Oncology
Companies in the same business, of comparable size and area, outside its group.
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- ATB Therapeutics Manufacture of basic pharmaceutical products Marche-en-Famenne · balance sheet €10.6m
- XpressBioX Manufacture of basic pharmaceutical products Herstal · balance sheet €8.92m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
Frequently asked questions about B.C. Oncology
What is the revenue of B.C. Oncology?
B.C. Oncology files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of B.C. Oncology?
In Belgium, the VAT number is the company number prefixed with BE: BE0629859206 for B.C. Oncology, if the company is VAT-registered. Its company number (CBE) is 0629.859.206.
Where is the registered office of B.C. Oncology?
According to the CBE register, the registered office of B.C. Oncology is in 1930 Zaventem.
What is the equity of B.C. Oncology?
At the close of the 2025 financial year, the equity of B.C. Oncology amounts to 9,482,028 €, a solvency of 99.8% of total assets.
Who manages B.C. Oncology?
The register lists 5 active mandates at B.C. Oncology. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is B.C. Oncology within its sector?
By total assets for 2025, B.C. Oncology ranks among the 100 largest of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of B.C. Oncology
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →